An Investigation Into the Feasibility of Beetroot Juice Supplementation in People Living With Alzheimer's Disease.

NCT ID: NCT07258004

Last Updated: 2025-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-03-31

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if taking a beetroot juice supplement will work in people living with Alzheimer's disease. The main questions it aims to answer are:

* Can people living with Alzheimer's disease realistically drink beetroot juice regularly (for example, is it easy to take, free from side effects and acceptable)?
* Does drinking beetroot juice twice a day improve health in people living with Alzheimer's disease?

Researchers will look at how you managed with the beetroot juice, as well as if there were any improvements in your health measures.

Participants will:

* Complete testing before and after the intervention for no more than 3 hours each time
* Complete a 1-day food diary before testing
* Take a beetroot juice supplementation twice daily for 1-week
* Keep a note of any problems with the beetroot juice

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objectives:

To establish the feasibility of a beetroot juice supplement in people living with Alzheimer's disease (primary outcome). To establish whether a twice per day, 1-week beetroot juice intervention will induce changes in dementia related health outcomes (secondary outcomes).

Outline:

Participants will complete a 24-hour food diary prior to baseline testing before starting twice daily supplementation of beetroot juice shots for 7 days. Post-testing will be conducted on day 8 with a further 24-hour food diary having been completed prior to testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beetroot juice supplementation

Group Type EXPERIMENTAL

Beetroot juice

Intervention Type DIETARY_SUPPLEMENT

Participants will take a concentrated beetroot juice shot (70ml) twice daily for 1-week. Each shot contains 400mg of dietary nitrate (800mg per day).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Beetroot juice

Participants will take a concentrated beetroot juice shot (70ml) twice daily for 1-week. Each shot contains 400mg of dietary nitrate (800mg per day).

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 65-85 years
* Mild or Moderate Alzheimer's disease
* Participants must be able to speak, read, and understand English to participate in this study.
* To support adherence, participants are asked to have a carer, partner, friend, or family member available to assist with reminders to take the shots twice daily.

Exclusion Criteria

* Advanced or severe Alzheimer's Disease
* Diagnosis of an additional neurological condition
* Have used antibiotics in the last month
* Use of mouthwash in the last month
* Use of medication affecting nitrate metabolism (for example proton pump inhibitors, Isosorbide Mononitrate, Sildenafil or Glyceryl Trinitrate).
* Unable to provide informed consent
* Allergies to beetroot
* Taking part in pharmacological trials
Minimum Eligible Age

65 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NHS Lanarkshire

OTHER_GOV

Sponsor Role collaborator

University of the West of Scotland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Scott Nicol Findlay

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rachel Kimble

Role: STUDY_DIRECTOR

University of the West of Scotland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of the West of Scotland

Glasgow, Lanarkshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Scott N Findlay

Role: CONTACT

+447909159194

Rachel Kimble

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Scott N Findlay

Role: primary

+447909159194

Rachel Kimble

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OMNI Feasibility trial

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sleep Trial to Prevent Alzheimer's Disease
NCT04629547 RECRUITING PHASE2